| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.37B | 2.44B | 2.17B | 1.80B | 1.98B |
| Gross Profit | 887.51M | 839.32M | 713.91M | 522.19M | 573.17M |
| EBITDA | 382.88M | 321.43M | 226.91M | 84.61M | 121.03M |
| Net Income | 301.06M | 239.10M | 96.92M | -9.73M | -81.25M |
Balance Sheet | |||||
| Total Assets | 3.72B | 3.41B | 2.60B | 2.38B | 2.39B |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 1.05B | 302.05M | 202.01M | 162.58M |
| Total Debt | 1.29B | 1.28B | 502.46M | 515.10M | 507.54M |
| Total Liabilities | 1.98B | 2.00B | 1.27B | 1.19B | 1.25B |
| Stockholders Equity | 1.72B | 1.39B | 1.31B | 1.17B | 1.12B |
Cash Flow | |||||
| Free Cash Flow | 380.85M | 207.61M | 98.09M | 4.75M | 110.36M |
| Operating Cash Flow | 403.74M | 238.18M | 124.97M | 24.50M | 145.04M |
| Investing Cash Flow | -349.65M | -63.41M | -23.31M | 40.52M | -34.88M |
| Financing Cash Flow | -95.25M | 579.57M | -3.51M | -18.74M | -152.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $6.90B | 44.07 | 21.34% | 0.16% | 13.13% | 24.02% | |
72 Outperform | $5.13B | 13.43 | 34.02% | 0.26% | 1.76% | 4.10% | |
71 Outperform | $4.29B | 38.15 | 20.71% | 0.82% | 12.11% | 16.45% | |
69 Neutral | $4.07B | 13.96 | 18.49% | ― | 0.14% | 14.12% | |
68 Neutral | $5.00B | 155.81 | 1.11% | 1.43% | -8.07% | 63.50% | |
66 Neutral | $6.90B | 42.40 | 9.86% | ― | 7.40% | 13.79% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
On February 23–26, 2026, Itron entered into a private Rule 144A offering and related agreements to issue $805 million of 0.00% Convertible Senior Notes due 2032, including full exercise of an additional $105 million option. The notes, which are senior unsecured obligations with a March 15, 2032 maturity, feature an initial conversion price of about $123.77 per share, complex conversion and redemption triggers, and potential additional interest of up to 0.50% tied to reporting and legend-removal conditions.
In connection with the deal, Itron executed capped call transactions covering roughly 6.5 million shares with a strike aligned to the conversion price and an initial cap of $190.42, paying about $92.8 million to multiple bank counterparties. The financing is structured to minimize dilution upon conversion while providing low-cost capital to refinance its 0.00% Convertible Senior Notes due 2026, fund up to $125 million of concurrent stock repurchases and support general corporate purposes, thereby strengthening the balance sheet and potentially supporting the share price.
The most recent analyst rating on (ITRI) stock is a Buy with a $128.00 price target. To see the full list of analyst forecasts on Itron stock, see the ITRI Stock Forecast page.